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Abstract: The antihypertensive effect of the soluble fraction of wine lees (WL) from Cabernet variety
grapes was recently reported by our group. This blood pressure (BP)-lowering effect was attributed to
the presence of flavanols and anthocyanins. In this context, phenolic-enriched wine lees (PWL) could
potentially exhibit a stronger bioactivity. Therefore, the aim of this study was to obtain a soluble
fraction of WL with increased phenolic content and evaluate its functionality. The PWL were obtained
using an enzyme-assisted extraction based on the hydrolysis of WL proteins with Flavourzyme®.
They contained 57.20% more total phenolic compounds than WL, with anthocyanins and flavanols
being the largest families present. In addition, PWL also showed greater angiotensin-converting
enzyme inhibitory and antioxidant activities. Finally, the antihypertensive activity of the PWL was
evaluated in spontaneously hypertensive rats. A single dose of 5 mL/kg body weight of PWL
showed a greater BP-lowering effect than the one shown by WL. Moreover, this antihypertensive
effect was more prolonged than the one produced by the antihypertensive drug Captopril. These
results demonstrate that enzymatic protein hydrolysis is a useful method to maximize the extraction
of phenolic compounds from WL and to obtain extracts with enhanced functionalities.
Keywords: hypertension; phenolic compounds; hydrolysate; spontaneously hypertensive rats;
bioactive compounds; enzymatic hydrolysis; UHPLC; grape by-products
1. Introduction
Nowadays, it is known that some dietary components play an important role in the
prevention of hypertension (HTN) [1]. Thus, an increase of fruit and vegetable intake
has been evidenced to reduce the risk of cardiovascular disease (CVD) in hypertensive
subjects [2,3]. Their health benefits are attributed to the presence and synergetic effect of
different bioactive compounds including fiber, vitamins or phenolic compounds [4]. In the
last two decades, phenolic compounds have been widely studied for their beneficial health
effects, including antihypertensive activity [5–7].
There are different mechanisms related to the blood pressure (BP)-lowering effect of
phenolic compounds. Some of these have been referred to their antioxidant capacity [6,8].
In fact, it has been reported for anthocyanin, flavanol or flavonol rich extracts that the
oxidative stress improvement is one of the mechanisms responsible for their antihyper-
tensive properties [9–11]. In addition, phenolic compounds can also act on HTN via the
inhibition of angiotensin-converting enzyme (ACE) [12]. This enzyme is key in the BP
regulation produced by the renin-angiotensin-aldosterone system (RAAS). In fact, ACE
inhibition is usually used in HTN treatment [13,14]. Although synthetic ACE inhibitors
such as Enalapril or Captopril are very efficient in reducing BP, in some cases they can cause
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unwanted side effects [15,16]. Thus, new antihypertensive compounds, acting on different
HTN targets, are being highly investigated, mainly from natural sources. In this regard, the
ACE inhibitory (ACEi) activity of different phenolic compounds has been demonstrated
in in vitro studies [17]. Phenolics do not reach the potency of drugs commonly used in
the treatment of HTN as Captopril but they may be considered as naturally functional
compounds since their dietary intake can be as high as 1 g/day [17].
Agri-food by-products have recently emerged as a new source of bioactive com-
pounds [18]. In this regard, winery by-products (seeds, skin, pomace, stems, or lees) have
been used to obtain extracts rich in phenolic compounds with antioxidant and/or anti-
hypertensive properties [10,11,19–21]. However, these phenolic compounds can be in the
food matrix in free form or covalently bound to soluble or insoluble substances [22]. For
example, tannins, phenolic compounds present in winery by-products, form complexes
with proteins [23]. Thus, extraction methods must be used to release these bioactive com-
pounds [22]. However, some of these methods produce residual substances and more
eco-friendly alternatives are being developed. In this regard, enzyme-assisted extraction
has emerged as a green technique that brakes or softens the cell wall to release bioactive
compounds [24]. Agri-food by-products contain macromolecules that can be susceptible to
hydrolysis such as proteins, cellulose, lignin or hemicellulose [25]. In fact, this reaction has
already been used to release phenolic compounds from the cell wall matrix [22]. Specifi-
cally, protein hydrolysis has been evidenced to be a good method to release proteins and
phenolic compounds [26,27].
Wine lees (WL), a winery by-product, account for 25% of the waste from the wine-
making process [28]. The Council Regulation (EEC) No. 337/79 defined this by-product
as “the residue that forms at the bottom of recipients containing wine, after fermentation,
during storage or after authorized treatments, as well as the residue obtained following the
filtration or centrifugation of this product” [29]. WL can be classified according to the stage
of the wine making process, as first-fermentation WL, second-fermentation WL, and aging
WL (after wine alcoholic fermentation, malolactic fermentation or aging in wood barrels,
respectively) [30]. WL can be separated into two phases after centrifugation or filtration of
WL, the solid and the liquid phases. The proportion of both phases can vary depending on
the type of WL or the procedure to obtain the WL, since water can be added to remove WL
from wine tanks. The solid phase is mainly composed of yeasts, insoluble carbohydrates,
phenolic compounds, proteins, lignin, tartrates, and other materials such as grape skins [31].
Regarding the soluble phase, this is composed of organic acids, ethanol, and soluble pheno-
lic compounds [19,31]. A previous study from our group evidenced the antihypertensive
effect of the soluble fraction of WL from grapes of the Cabernet variety [19]. Phenolic
analysis revealed that this fraction was rich in flavanols and anthocyanins. However, since
only a centrifugation was performed and no particular extraction method was applied,
phenolic compounds from the non-soluble fraction of WL were not extracted. In this regard,
the presence of phenolic compounds in the solid fraction, bound to yeast cell walls, has
been reported [32]. Enzymatic-assisted extraction using Glucanex® and Mannaway® (β-1,
3 glucanase and β-1,4-mannanase activities, respectively) has been efficiently used in WL as
treatment previous to a solid–liquid extraction to release anthocyanins or glycocompounds
from the non-soluble fraction [33,34]. Considering this evidence, the aim of this study was
to increase the release of WL phenolic compounds by protein hydrolysis of WL to maximize
the phenolic yield, improving the valorization of this by-product. The antioxidant, ACEi
and antihypertensive activities of the phenolic-enriched WL (PWL) were also evaluated.
2. Materials and Methods
2.1. Chemicals and Reagents
Flavourzyme® 1000 L (EC 3.4.11.1, 500 leucine amino peptidase units (LAPU)/g
from Aspergillus oryzae) was kindly provided by Novozymes (Bagsværd, Denmark). ACE
(EC 3.4.15.1), 2,2-diphenyl-1-picryl-hydrazyl-hydrate (DPPH), picrylsulfonic acid and
acetonitrile for HPLC were purchased from Sigma-Aldrich (Madrid, Spain). Captopril
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(PubChem CID: 44093) and resveratrol were provided by Santa Cruz Biotechnology (Dallas,
TX, USA) and Carl Roth (Karlsruhe, Germany), respectively. Folin–Ciocalteu reagent,
coumaric acid, quercetin, gallic acid, catechin, and epicatechin were purchased from
Fluka/Sigma-Aldrich. 4-Hydroxybenzoic acid, caffeic acid, procyanidin dimer B2, vanillic
acid, and malvidin-3-O-glucoside were purchased from Extrasynthése (Lyon, France).
Ferulic acid, cyanidin-3-O-rutinoside, and peonidin-3-O-rutinoside were purchased from
PhytoLab (Vestenbergsgreuth, Germany). Analytical grade reagents were always used.
2.2. Preparation of the Wine Lees Hydrolysate
WL were kindly provided by the cellar Grandes Vinos y Viñedos S.A (Cariñena PDO
area, Cariñena, Spain). They were collected after racking the red wine (first-fermentation
WL), which was made from grapes of Cabernet variety. The preparation of the new
PWL was as follows: 10 mL of WL were mixed with the commercial enzyme solution
Flavourzyme® (enzyme/substrate ratio, 80 LAPU/g protein). Hydrolysis was carried out
at 25 ◦C for 2 h at pH 4.0 and 250 rpm in a MaxQ Orbital Shaker Thermo Scientific (Thermo
Fisher Scientific, Waltham, MA, USA). These enzymatic conditions were set according
to a previous study focus on selecting the most appropriate enzymatic preparation and
choosing process conditions easily applicable on an industrial scale (data not shown).
Reaction was finished adding 1 M HCl to decrease the solution pH to 3. The final volume
of the hydrolysate was 11.25 mL. Subsequently, the hydrolysate was centrifuged at 3000× g
for 15 min at 4 ◦C to eliminate non-soluble particles and the supernatant (PWL) was
collected for analysis. In addition, no-hydrolysis control WL (0 WL) was also subjected to
the same procedure but replacing the enzyme volume by Milli-Q water.
2.3. Characterization of Wine Lees
Initial WL consisted of 28.0 ± 6.6% (w/v) solid, determined by AOAC official method [35],
27.14 ± 1.13% ((w/(w), protein, determined applying the factor 6.25 to the total nitro-
gen content measured by the Kjeldahl method [35] and 100.50 ± 1.36 mg GA/g total
phenolic compound contents, determined by the Folin–Ciocalteu method according to
Iglesias-Carres et al. [36]. Gallic acid (GA) was used as the calibration curve (40–400 mg/L)
and mg GA equivalents per mL of WL (mg GAE/mL) were used to express the results.
Protein and total polyphenol contents were expressed per gram of dry weight. The analysis
was done in triplicate.
The percentage of solid (%, (w/(v) and total protein contents (%, (w/w) of both 0
WL and PWL were determined according the AOAC official methods [35] and total phe-
nolic compounds (mg GAE/g of dry weight), were determined by the Folin–Ciocalteu
method [36], as already mentioned. The determination of the total amino acid content
was carried out following the method described by Mas-Capdevila et al. [37]. Briefly,
proteins in the samples suffered both acidic and basic hydrolysis under heat conditions for
1.5 h using increasing temperatures up to 150 ◦C. Identification and quantification of the
amino acids in the samples were performed using high-performance liquid chromatogra-
phy coupled to electrospray ionization and quadrupole time-of-flight mass spectrometry
(UHPLC-Q-TOF/MS). All analyses were done at least in duplicate.
The hydrolysis degree of the PWL was determined by the TNBS (2,4,6-trinitrobenzenes
ulfonic acid) method according to Aldler–Nissen through the determination of free α-amino
acid groups [38]. Total hydrolysis was performed adding 6 N HCl to the sample, incubating
it for 24 h at 110 ◦C. Leucine was used as a calibration curve. The protein content used to
calculate the hydrolysis degree was the one obtained by the Kjeldahl method. The analysis
was done in triplicate.
All the analyses were carried out using the samples directly without any extrac-
tion method.
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2.4. Identification and Quantification of the Phenolic Profile
The phenolic profiles of 0 WL and PWL were also analyzed. Separation, identifica-
tion, and quantification of anthocyanin and non-anthocyanin phenolic compounds were
performed following the method described by López–Fernández–Sobrino et al. [19]. 0 WL
and PWL were diluted with water:methanol (50:50, v:v) and directly injected in a 1290 UH-
PLC Infinity II series coupled to a Q-TOF/MS 6550 (Agilent Technologies, Palo Alto, CA,
USA). Both positive and negative ionization ([M-H]– or [M-H]+) were used to identify
parental ions and fragmentation patterns as shown by López–Fernández–Sobrino et al. [19].
Commercial standards were used to construct a calibration curve to carry out the quanti-
tative analysis of coumaric acid, procyanidin dimer B2, quercetin, catechin, epicatechin,
4-hydroxybenzoic acid, gallic acid, malvidin-3-O-glucoside, caffeic acid, vanillic acid, fer-
ulic acid, cyanidin-3-O-rutinoside, peonidin-3-O-rutinoside, and resveratrol. For the rest
of the compounds, the analysis was semi-quantitative using the calibration curve of the
commercial standard having the most similar structure to the analyzed compound.
2.5. Antioxidant Activity
DPPH assay was used to determine the antioxidant activity of both samples following
the method described by Shen et al. 2010 [39] with some modifications. An aliquot of
500 µL of sample was mixed with 200 µL of DPPH 0.5 mM (in ethanol). After vortexing, the
samples were kept in the dark at room temperature for 30 min. Absorbance was measured
at 517 nm. Ascorbic acid was used as a positive control, and samples were diluted in
ethanol at different concentrations (0–400 µg/mL). A non-lineal fit was performed on the
experimental data to calculate the EC50, that is the quantity necessary to reduce 50% of
radical scavenging. DPPH radical scavenging activity was expressed as percentage of
activity (%) or EC50 (µg of dry weight/mL of dissolution). Data are presented as the mean
value of three determinations ± SD.
2.6. ACE Inhibitory Activity
ACEi activity was determined according to López–Fernández–Sobrino et al. [19].
The method uses the fluorescence compound o-Abz-Gly-p-Phe(NO2)-Pro-OH as ACE
substrate. In the presence of an ACE inhibitor, a partial or total loss of fluorescence is
produced during the reaction depending on the ACE inhibitory potential of the studied
compound. Specifically, in this study, fluorescence was measured at 30 min (37 ◦C), using
360 nm and 400 nm as excitation and emission wavelengths respectively. ACEi activity
was expressed as percentage of inhibition (%) or IC50 (µg of dry weight/mL of dissolution).
The comparison of the percentage of ACEi activity of both WL was carried out using the
same volume of the samples, 0.16 µL. IC50 was calculated by constructing a dose-response
curve. A linear approximation regression was used. Data are presented as the mean value
of three determinations ± SD. Captopril, a synthetic ACE inhibitor, was used to validate
the methodology.
2.7. Antihypertensive Effect
Male spontaneously hypertensive rats (SHR) (17–20 weeks old, weighing 350–400 g)
were purchased from Charles River Laboratories España S.A. (Barcelona, Spain). Rats were
singly housed in a temperature-controlled animal quarter (22 ◦C) with a 12 h light/dark
period. During the experiment, they had free access to standard chow (Panlab A04, Panlab,
Barcelona, Spain) and to water.
After a 10-day adaptation period and two weeks of a training period, animals were
given a single dose of the different tested compounds between 9 and 10 a.m. by oral
gavage. A dose of 5 mL/kg body weight (bw) of PWL and 0 WL was administered to SHR.
Captopril (50 mg/kg bw, a known antihypertensive drug) and tap water were used as
controls (positive and negative, respectively).
BP was measured in the SHR before and after (2, 4, 6, 8, 24, 48, and 72 h) administra-
tion of treatments, using the tail-cuff method and the LE 5002 system (Letica, Hospitalet,
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Barcelona, Spain) according to Quiñones et al. [40]. Prior to BP measurements and to facili-
tate the detection of the tail artery pulsations, SHR were kept at 38 ◦C for 10 min. Changes
in systolic and diastolic BP (SBP and DBP, respectively) were expressed as the differences
in these variables before and after the administration for each treatment. Data are shown
as the mean values ± standard error of mean (SEM) for a minimum of six experiments. BP
measurements were recorded by the same person in a peaceful environment to minimize
stress-induced variations.
Experimental in vivo studies were carried out following the European Communities
Council Directive (86/609/EEC). In addition, the protocol was reviewed and approved by
the Animal Ethics Review Committee for Animal Experimentation of the Universitat Rovira
i Virgili and further approved by Generalitat de Catalunya (permission number 10780).
2.8. Statistical Analysis
Differences between 0 WL and the PWL in their amino acid content, total phenolic
content, phenolic profile, antioxidant activity, and ACEi activity were analyzed by Student’s
T-test. Two-way analysis of variance (two-way ANOVA) and Tukey test as post hoc
were used to detect differences between treatments in BP over the evaluated time. One-
way ANOVA was used to analyze the BP treatment differences at a specific time point.
Differences between compounds were considered significant when p < 0.05. GraphPad
Prism 7.04 for Windows (GraphPad Software, San Diego, CA, USA) was used to perform
the statistical analysis. Grubbs’ test was used to detect outliers.
3. Results
3.1. Wine Lees Composition
Samples were characterized according to their humidity, total protein, total amino
acid, total phenolic content, and hydrolysis degree. Solid contents of 0 WL and PWL were
2.49 ± 0.05% and 2.78 ± 0.16%, respectively. Total protein contents of the 0 WL and PWL
were 26.08 ± 0.60 and 27.50 ± 0.71%, respectively. Total amino acid compositions of the
0 WL and PWL are shown in Table 1. The amino acid content of the 0 WL was 24.83 mg/g
of dry product, with Pro being the major amino acid found. Regarding PWL, total amino
acid concentration was 1.7 times higher (41.20 mg/g of dry product) than the one shown
by the WL without hydrolysis. An increase in the content of Pro, Leu, Ile and Val (1.4, 6.6,
5.6 and 5.5 times higher, respectively) was observed in the hydrolysate compared to the
0 WL. In addition, PWL also contained Trp, while this amino acid residue was not found in
the 0 WL. The hydrolysis degree of the PWL was 7.61 ± 0.65%.
Total phenolic content of PWL, measured by the Folin–Ciocalteu method, was
160.06 ± 0.32 mg GAE/g, significantly higher than the one observed by 0 WL (148.03 ± 0.48 mg
GAE/g).
3.2. Determination of the Phenolic Profile in Wine Lees Samples
Phenolic profiles of the 0 WL and PWL were determined. As example, Figure 1 shows
the PWL phenolic profile of non-anthocyanin (Figure 1A) and anthocyanin (Figure 1B)
analyzed by UHPLC-(ESI)-Q-TOF-MS. The total amount of phenolic compounds in the
PWL was significantly higher than the one shown by 0 WL (15.59 mg/g and 24.50 mg/g,
respectively) (Figure 2A). This increase was observed in all phenolic families following this
order: anthocyanins > flavonols > flavanols > phenolic acids > stilbenes (Figure 2A).
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Table 1. Total amino acid content of 0 WL and PWL by UHPLC-Q-TOF/MS.
Amino Acids 0 WL (µg/g) PWL (µg/g)
Alanine 706.3 ± 62.8 854.5 ± 70.1
Arginine 110.5 ± 12.5 195.2 ± 19.9
Asparagine 273.6 ± 59.5 417.6 ± 91.0
Aspartate 307.9 ± 37.4 702.9 ± 78.3
Glutamate 1086.1 ± 265.5 1278.4 ± 325.8
Glutamine N.D N.D
Glycine 345.5 ± 65.2 442.1 ± 68.8
Histidine 75.6 ± 9.3 135.4 ± 7.2
Isoleucine 358.8 ± 54.7 2014.6 ± 256.2 **
Leucine 435.8 ± 74.4 2857.6 ± 445.7 **
Lysine 143.7 ± 28.2 238.4 ± 46.6
Phenylalanine 64.9 ± 11.7 189.9 ± 34.8
Proline 19,828.7 ± 1230.8 28,623.8 ± 1761.1 **
Serine 517.0 ± 188.6 1091.9 ± 348.0
Threonine 326.2 ± 87.7 720.5 ± 181.0
Tryptohan N.D 52.9 ± 18.6 *
Tyrosine 46.8 ± 7.2 152.8 ± 19.9
Valine 181.7 ± 29.4 1187.0 ± 172.4 *




N.D: no detected. Data are expressed as mean (µg/g of dry sample) ± SD. Statistical differences by Student’s
T-test between control wine lees (0 WL) and phenolic-enriched wine lees (PWL) are indicated as (*) when p < 0.05
and (**) when p < 0.01.
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Table 2. Non-anthocyanin characterization by UHPLC-(ESI-)-Q-TOF-MS in 0 WL and PWL.
Compound R.T. (min) [M-H]- Fragment (m/z) 0 WL (µg/g) PWL (µg/g)
Flavanols
1 Catechin 8.17 289.0718 2681.20 ± 19.20 3289.60 ± 20.80 *
2 Catechin gallate a 6.66 441.0827 289.07209 18.00 ± 0.40 16.40 ± 0.40 **
3 Epicatechin 9.96 289.0718 1035.60 ± 6.00 1242.00 ± 6.80 *
4 (Epi)catechin O-glucoside iso1 b 6.55 451.1246 289.0721 20.80 ± 0.00 22.80 ± 0.00 *
5 (Epi)catechin O-glucoside iso2 b 7.41 451.1246 289.0721 10.80 ± 0.00 16.40 ± 0.00 *
6 (Epi)catechin O-glucoside iso3 b 8.37 451.1246 289.0721 62.80 ± 1.20 70.80 ± 1.20 *
7 Procyanidin dimer B2 9.30 577.1387 289.0733 514.40 ± 0.40 634.00 ± 0.40 **
8 Procyanidin dimer iso1 c 7.68 577.1387 289.0733 1020.80 ± 6.00 1178.00 ± 6.40 *
9 Procyanidin dimer iso2 c 7.97 577.1387 289.0733 276.80 ± 2.00 334.40 ± 2.00 *
10 Procyanidin dimer iso3 c 8.18 577.1387 289.0733 85.20 ± 0.80 86.80 ± 0.40
11 Procyanidin dimer iso4 c 8.99 577.1387 289.0733 211.20 ± 0.00 262.80 ± 0.00 *
12 Procyanidin dimer iso5 c 11.14 577.1387 289.0733 70.40 ± 0.80 106.00 ± 1.20
13 Procyanidin trimer iso1 c 5.46 865.2016 577.1369 206.00 ± 4.00 251.60 ± 4.40
14 Procyanidin trimer iso2 c 8.67 865.2016 577.1369 184.00 ± 10.40 274.00 ± 13.60 *
15 Procyanidin trimer iso3 c 8.89 865.2016 577.1369 72.40 ± 0.40 84.00 ± 0.40 *
16 Procyanidin trimer iso4 c 10.55 865.2016 577.1369 68.80 ± 3.60 89.60 ± 0.40 *
17 Procyanidin trimer iso5 c 10.71 865.2016 577.1369 177.60 ± 3.60 265.60 ± 4.40 *
Flavonols
18 Quercetin 17.80 301.0372 888.40 ± 4.80 1954.40 ± 9.20 **
19 Quercetin-3-O-glucoside d 13.00 463.0904 301.0361 19.20 ± 0.40 48.40 ± 1.20 **
20 Quercetin-3-O-glucuronide d 12.95 477.0702 301.0369 115.20 ± 0.80 255.20 ± 1.20 **
21 Kaempferol d 20.07 285.0405 319.60 ± 1.60 632.00 ± 2.40 **
22 Kaempferol-3-O-glucuronide d 14.22 461.0763 285.0412 27.60 ± 0.40 66.00 ± 0.80 **
23 Isorhamnetin d 20.31 315.0531 203.20 ± 2.40 481.60 ± 5.20 **
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Table 2. Cont.
Compound R.T. (min) [M-H]- Fragment (m/z) 0 WL (µg/g) PWL (µg/g)
Phenolic acids
24 Gallic acid 3.13 169.0193 2734.80 ± 93.60 3496.80 ± 106.40
25 Caffeic acid 8.63 179.0401 70.80 ± 0.80 97.20 ± 1.20 *
26 Caffeic acid O-glucoside iso1 e 7.64 341.0878 179.0350 22.40 ± 0.80 23.20 ± 0.80
27 Caffeic acid O-glucoside iso2 e 8.29 341.0878 179.0350 22.40 ± 1.20 19.60 ± 0.80
28 p-Coumaric acid 10.65 163.0439 28.00 ± 0.40 117.60 ± 1.20 **
29 4-Hydroxybenzoic acid 8.17 137.0243 58.40 ± 2.00 66.40 ± 2.00
30 Ferulic acid 12.00 193.0506 13.20 ± 0.40 18.80 ± 0.40 *
31 Vanillic acid 8.51 167.0350 76.40 ± 2.40 90.40 ± 2.80
Stilbenes
32 trans-Resveratrol f 15.73 227.0714 120.40 ± 0.80 164.00 ± 0.80 **
33 Resveratrol iso1 f 18.00 227.0714 66.00 ± 0.40 152.40 ± 0.80 **
34 Resveratrol O-glucoside iso1 f 12.44 389.1242 227.0721 30.00 ± 0.40 56.40 ± 0.80 **
35 Resveratrol O-glucoside iso2 f 14.92 389.1242 227.0721 88.00 ± 1.60 138.00 ± 2.40 **
36 Piceatannol f 2.59 243.0663 203.0727 124.40 ± 2.00 136.80 ± 1.60 *
37 Piceatannol 3-O-glucoside iso1 f 12.89 405.1208 243.0670 5.60 ± 0.00 9.60 ± 0.40 *
38 Piceatannol 3-O-glucoside iso2 f 13.15 405.1208 243.0670 2.40 ± 0.00 4.80 ± 0.00 *
39 Viniferin-iso1 f 19.53 453.1344 116.9291 4.40 ± 0.00 6.40 ± 0.00 *
40 Viniferin-iso2 f 19.92 453.1344 116.9291 20.80 ± 0.40 29.20 ± 0.80 *
Abbreviations: Retention time (R.T.); Control WL (0 WL); Phenolic-enriched wine lees (PWL). a Quantified using catechin calibration curve. b Quantified using epicatechin calibration curve. c Quantified using
procyanidin dimer B2 calibration curve. d Quantified using quercetin calibration curve. e Quantified the caffeic acid calibration curve. f Quantified using resveratrol calibration curve. Statistical differences by
Student’s t-test between 0 WL and PWL are indicated (*) when p < 0.05 and (**) when p < 0.01.
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Table 3. Anthocyanin characterization by UHPLC-(ESI+)-Q-TOF-MS in 0 WL and PWL.
Anthocyanins R.T. (min) [M-H]+ Fragment (m/z) 0 WL (µg/g) PWL (µg/g)
1 Gallocatechin-malvidin-3-glucoside dimer a 3.58 797.2035 1.60 ± 0.04 4.46 ± 0.11 *
2 Malvidin-3-glucoside-(epi)catechin a 4.84 781.1974 16.67 ± 0.13 19.27 ± 0.14 *
3 Delphinidin-3-glucoside b 5.06 465.1028 303.0511 184.88 ± 1.82 573.34 ± 5.64 **
4 Cyanidin-3-glucoside b 5.85 449.1078 287.0531 21.72 ± 0.81 48.11 ± 1.79 *
5 Petunidin-3-glucoside c 6.47 479.1184 317.0669 195.11 ± 2.26 513.73 ± 5.96 **
6 Petunidin-3-glucoside-pyruvic acid c 7.05 547.1082 385.0547 1.61 ± 0.04 3.54 ± 0.09 *
7 Peonidin-3-glucoside c 7.14 463.1235 301.0717 151.78 ± 2.50 312.22 ± 5.14 *
8 Malvidin-3-glucoside a 7.48 493.1341 331.0843 1780.76 ± 20.01 3334.75 ± 37.47 *
9 Peonidin-3-glucoside-pyruvic acid c 7.81 531.1133 369.0607 0.93 ± 0.03 1.90 ± 0.06 *
10 Delphinidin-(6-acetyl)-3-glucoside b 7.87 507.1133 303.0496 47.82 ± 0.90 151.91 ± 2.85 *
11 Visitin A (malvidin-3-glucoside-pyruvic acid) a 8.11 561.1239 399.0730 14.80 ± 0.13 31.02 ± 0.27 **
12 Visitin B (malvidin-3-glucoside-acetaldehyde) a 8.32 517.1341 355.0826 24.08 ± 0.59 70.03 ± 1.73 *
13 Malvidin-3-glucoside-ethyl-(epi)catechin a 8.40 809.2287 4.62 ± 0.03 8.91 ± 0.05 *
14 Cyanidin-(6-acetyl)-3-glucoside b 8.45 491.1184 491.1189 15.21 ± 0.23 33.29 ± 0.50 *
15 Acetylvisitin A a 8.50 603.1344 399.0718 13.66 ± 0.44 19.65 ± 0.63 *
16 Malvidin-3-glucoside-ethyl-(epi)catechin a 8.57 809.2287 17.54 ± 0.24 31.82 ± 0.43 *
17 Petunidin-(6-acetyl)-3-glucoside c 8.66 521.1378 317.0667 55.81 ± 1.87 150.18 ± 5.04 **
18 Malvidin-3-glucoside-ethyl-(epi)catechin a 8.75 809.2287 22.92 ± 0.73 42.10 ± 1.34 **
19 Acetylvisitin B a 8.77 559.1446 355.0813 14.50 ± 0.44 36.86 ± 1.12 *
20 Peonidin-(6-acetyl)-3-glucoside c 9.08 505.1341 301.0714 55.47 ± 1.24 124.75 ± 2.80 *
21 Delphinidin-(6-coumaroyl)-3-glucoside b 9.08 611.1395 303.0508 14.72 ± 0.27 48.48 ± 0.89 *
22 Malvidin-(6-acetyl)-3-glucoside a 9.13 535.1446 331.0836 727.35 ± 0.84 1503.53 ± 1.74 **
23 Coumaroylvisitin A a 9.29 707.1607 399.0718 2.88 ± 0.07 6.18 ± 0.15 *
24 Malvidin-(6-caffeoyl)-3-glucoside a 9.41 655.1657 331.0808 5.99 ± 0.27 13.98 ± 0.63 *
25 Cyanidin-(6-coumaroyl)-3-glucoside b 9.42 595.1446 287.0560 5.01 ± 0.16 13.77 ± 0.43 *
26 Catechin-ethyl-malvidin-3-acetylglucoside dimer a 9.43 851.2511 10.30 ± 0.31 19.05 ± 0.56 **
27 Petunidin-(6-coumaroyl)-3-glucoside c 9.52 625.1552 317.0662 21.11 ± 0.36 63.19 ± 1.08 *
28 Pinotin A (malvidin-3-glucoside-vinylcatechol) a 9.53 625.1552 463.0998 23.80 ± 0.51 71.25 ± 1.52 *
29 Malvidin-glucoside-vinyl-catechin a 9.56 805.1974 1.46 ± 0.03 4.23 ± 0.09 *
30 Coumaroylvisitin B a 9.58 663.1708 355.0822 8.53 ± 0.28 23.20 ± 0.76 *
31 Malvidin-3-glucoside-vinylguaiacol a 9.63 639.1708 331.0823 10.07 ± 0.20 27.49 ± 0.54 *
32 Catechin-ethyl-malvidin-3-coumaroylglucoside dimer a 9.70 955.2785 5.95 ± 0.11 13.77 ± 0.25 *
33 Catechin-ethyl-malvidin-3-acetylglucoside dimer a 9.81 851.2511 1.93 ± 0.06 4.27 ± 0.14 *
34 Peonidin-(6-coumaroyl)-3-glucoside c 9.87 609.1603 301.0716 38.72 ± 1.08 85.15 ± 2.37 *
35 Malvidin-(6-coumaroyl)-3-glucoside a 9.92 639.1708 331.0823 274.63 ± 0.60 768.26 ± 1.69 **
36 Malvidin-glucoside-vinyl-catechin a 9.99 805.1974 1.58 ± 0.02 3.74 ± 0.05 **
37 Acetyl-pinotin A a 10.19 667.1657 0.08 ± 0.00 0.26 ± 0.00 *
38 Malvidin 3-O-glucoside 4-vinylphenol (Pigment A) a 10.22 609.1603 447.1079 7.40 ± 0.08 19.53 ± 0.21 **
39 Catechin-ethyl-malvidin-3-coumaroylglucoside dimer a 10.33 955.2785 1.14 ± 0.01 3.06 ± 0.02 *
40 Malvidin acetyl 3-O-glucoside 4-vinylphenol(Acetyl-pigment A) a 10.50 651.1708 447.1076 4.46 ± 0.17 10.42 ± 0.39 *
Abbreviations: Retention time (R.T.); Control WL (0 WL); Phenolic-enriched wine lees (PWL). a Quantified using calibration curve of malvidin-3-O-glucoside. b Quantified using calibration curve of
cyanidin-3-O-rutinoside. c Quantified using calibration curve of peonidin-3-O-rutinoside. Statistical differences by Student t-test between 0 WLE and PWL are indicated (*) when p < 0.05 and (**) when p < 0.01.
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Flavanols were the main family of phenolic compounds in the 0 WL, representing
43.1 % of total phenolic content, followed by anthocyanins (24.4 %, Figure 2B). However,
in the PWL, flavanols and anthocyanins were found in the same proportion (33.6 % and
33.5 % of the total phenolic compounds, respectively; Figure 2B). Tables 2 and 3 show
the individual phenolic compounds content in both 0 WL and PWL. A total amount of
40 non-anthocyanins and 40 anthocyanins were identified by UHPLC-ESI-Q-TOF-MS, re-
spectively. The major components in PWL were gallic acid (3.5 mg/g), catechin (3.3 mg/g),
malvidin-3-glucoside (3.3 mg/g), procyanidin dimers (2.6 mg/g), quercetin (2.0 mg/g),
malvidin-(6-acetyl)-3-glucoside (1.5 mg/g), and epicatechin (1.2 mg/g). Protein hydrolysis
released large amounts of anthocyanins, especially delphinidin-3-glucoside, petunidin-
3-glucoside, malvidin-(6-acetyl)-3-glucoside, malvidin-(6-coumaroyl)-3-glucoside, and
malvidin-3-glucoside. Within the family of flavanols, catechin, epicatechin, and pro-
cyanidin dimer B2 were those that showed the greatest increase after hydrolysis. All the
identified compounds of the flavonol family suffered an increase between 97.7–152.1%
in their content after hydrolysis (Table 2), quercetin being the major flavonol. Regarding
phenolic acids, the main increase after the hydrolysis was observed in p-coumaric acid.
While, resveratrol and its derivatives were the stilbenes that presented the highest release
after hydrolysis of WL.
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3.3. Antioxidant and ACEi Activities of the Wine Lees
Figure 3A shows an example of a dose–response curve of both wine lees used to deter-
mine their antioxidant activity as DPPH radical scavenging activity (%). EC50 values were
12.89 ± 0.72 µg/mL and 8.14 ± 0.81 µg/mL in the 0 WL and PWL, respectively (Figure 3B).
ACEi activity of the samples was also evaluated. The PWL showed a higher ACEi activity
than the 0 WL (53.6 and 35.7 %, respectively at 0.59 mg/mL) (Figure 3C). According to
these percentages, the IC50 value was lower in the hydrolysate (0.63 ± 0.02 mg/mL) in
comparison with the control 0 WL (0.74 ± 0.06 mg/mL) (Figure 3D).
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3.4. Antihypertensive Activity of the Wine Lees
The antihypertensive effect of both 0 WL and PWL was evaluated in SHR at 5 mL/kg
bw. is dose is equivalent to the doses of 18.50 20.01 mg GAE/kg bw a d 1.95 nd
3.06 mg/kg bw of phenolic compoun s determined by UHPLC-(ESI)-Q-TOF-MS for 0 WL
and PWL, respectively.
Water and Captopril (50 mg/kg bw) were used as negative and positive controls,
respectively. Prior to oral treatment administration, animals presented SBP and DBP values
characteristic of the hypertensive condition (205.6 ± 3.6 mmHg and 164.7 ± 10.0 mmHg,
respectively). As shown in Figure 4, the administration of water to animals did not signifi-
cantly change either SBP or DBP during the experiment. However, Captopril produced
a decrease in SBP in SHR after 2 h of its administration, its maximum being at 6 h post-
adm nistration (−41.3 ± 3.2 mm Hg) (Figure 4A). The sam pattern of SBP drop occurred
after administration of 0 WL. A maximum SBP reduction of −32.5 ± 2.3 m Hg was ob-
served at 6 h post-administration. Regarding the effect of the PWL, the maximum SBP
decrease was observed at 4–6 h post-administration (−32.3 ± 1.5 and −35.6 ± mmHg,
respectively). Notably, the BP lowering effect of PWL was greater than the antihypertensive
effect shown by 0 WL. Interestingly, no significant differences were found between the
antihypertensive effect of Captopril and PWL (two-way ANOVA). In addition, the dura-
tion of the effect was different. The antihypertensive effect produced by PWL was more
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prolonged than the one showed by 0 WL or Captopril. Basal SBP levels were recovered at
24, 48, and 72 h post-administration for 0 WL, Captopril and PWL, respectively.
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Figure 4. Changes in systolic (A) and diastolic (B) blood pressure (SBP and DBP, respectively) in
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represent significant differences (p < 0.05). p was estimated by two-way ANOVA.
Regarding DBP values, Captopril ad inistration also produced a significant re-
duction, reaching a maximum decrease 4 h post-administration (−42.7 ± 5.2 mmHg)
(Figure 4B). The antihypertensive effect was observed up to 24 h after Captopril admin-
istration. 0 WL and the hydrolysate also produced a significant antihypertensive effect
from 2 h post-administration, reaching the maximum DBP values at 6 h (−32.2 ± 5.2 and
−35.2 ± 1.2 mmHg, respectively). No differences in DBP were found between the two WL
sampl s under study.
4. Discussion
Winery by-products such as seeds, pomace or skin, have shown to be rich in phenolic
compounds [41]. In fact, these by-products of the winemaking process have been used to
obtain xtracts, rich in phenolic compounds with beneficial properties such as antioxidant
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or antihypertensive activities [9–11,19,21]. However, some of the phenolic compounds
are located inside the cells (and in some cases bound to different compounds such as
proteins) making it difficult to remove them from the food matrix and therefore decreasing
their full potential [42]. Recently, our group demonstrated the antihypertensive effect of
a soluble fraction of WL from Cabernet variety after its acute administration (5 mL/kg
bw) to SHR [19]. This effect was attributed to their high content of phenolic compounds.
Nevertheless, this fraction did not contain the non-soluble phenolic compounds since no
method of extraction was applied.
Different methodologies have been described to facilitate the release of phenolic
compounds from the matrix [43]. Enzyme-assisted extraction has emerged as a more
eco-friendly alternative to conventional solvent-based extraction methods [24]. In addition,
enzymatic hydrolysis is a more efficient extraction method that increases the extractability
of phenolic compounds from the food matrix (including those non-extractable as proan-
thocyanidins) using neither organic solvents nor any other toxic chemicals. Moreover, it
is a cost-efficient method to convert by-products into new and safe food ingredients or
products with enhanced nutritional value and functionality [25]. This technique is based on
the use of enzymes to break down different components of the cell to enhance the release
of phenolic compounds [26].
Therefore, since WL with a higher content in phenolic compounds could potentially
exhibit a stronger functionality, enzyme-assisted extraction was used to release the phe-
nolic compounds present in the non-soluble fraction of WL. The enzymatic preparation
Flavourzyme® was used because it is widely used for protein hydrolysis in industrial and
research applications [44]. To the best of our knowledge, it is the first time that this method
has been used in WL to extract phenolic compounds. The results showed changes in the
amino acid composition of PWL with respect to 0 WL, indicating that protein hydroly-
sis occurred. This protein hydrolysis was expected since Flavourzyme® is an enzymatic
preparation with peptidase activity. The amino acid residues Pro, Ile, Leu, Val, and Trp
were those that increased their content in the WL hydrolysate (PWL) more than the 0 WL
control. In addition, the hydrolysis of WL also produced an increase in the phenol con-
tent quantified by the Folin–Ciocalteu method and by UHPLC-(ESI-)-Q-TOF-MS, which
increased 57.20%.
The specific locations of phenolic compounds, their type of bonding and possible phys-
ical entrapment in WL is largely unknown at present. Methods such as ultrasound [45,46]
and microwave [47] assisted extraction have been used to enhance the extraction of active
compounds from many vegetable matrixes, including WL. In this study, enzyme-assisted
extraction using Flavourzyme® was demonstrated to be a useful technique to release pheno-
lic compounds from WL. In concordance with these results, Senevirathne et al. showed that
the hydrolysis of blueberries, with different enzymes, including the enzymatic preparation
Flavourzyme®, released phenolic compounds [48]. In the process of wine maceration, the
phenolic compounds from grapes are transferred to wine. However, a high proportion of
these compounds remains in winery by-products such as WL. The presence of phenolic
compounds in WL is due to the great adsorption capacity of the yeast cell wall used in
the winemaking process [49]. The phenolic profile present in the WL depends on the
type of grapes and other factors involved in the winemaking [50]. The WL used in this
study were obtained from grapes of the variety Cabernet, and their functionality was
linked to the high amount of anthocyanins and flavanols present in these lees [19]. In this
study, the hydrolysis of WL caused an increase in content of all the phenolic compound
families. However, anthocyanins and flavonols were the categories of polyphenols whose
concentration increased more in the PWL compared to WL, doubling both their content.
Regarding the phenolic profile, PWL were especially rich in flavanols (33.56%) and an-
thocyanin (33.52%), the flavanols being catechin and epicatechin and the anthocyanins
delphinidin-3-glucoside, petunidin-3-glucoside, and malvidin-(6-acetyl)-3-glucoside, the
most increased by the hydrolysis process. Thus, the application of this enzymatic-assisted
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extraction method to WL produced PWL rich in gallic acid, catechin, malvidin-3-glucoside,
procyanidin dimers, quercetin, malvidin-(6-acetyl)-3-glucoside, and epicatechin.
Phenolic compounds exhibit numerous beneficial effects. Among them, their radical
scavenging capacity stands out, giving them antioxidant properties [5]. Thus, since the
hydrolysis causes a release of phenolic compounds, PWL should show a higher antioxidant
capacity than 0 WL. The results in this study showed that both samples presented antioxi-
dant activity although, as expected, the hydrolysate presented a more potent antioxidant
capacity. This improvement in the antioxidant effect could be linked to the higher content of
anthocyanins, since a good correlation between anthocyanin compounds and antioxidant
activity has been reported for different WL extracts [51]. Both DPPH radical scavenging
activities are higher than previously reported for other winery by-products, i.e., a grape
stem phenolic extract [20,52]. Along with other beneficial effects, the antioxidant properties
of phenolic compounds have also been related to the improvement of HTN [53,54]. In fact,
one of the underlying mechanisms involved in the endothelial damage is oxidative stress,
which increases the contractibility of the vascular smooth muscle and promotes its prolifer-
ation [55]. Furthermore, free radicals in the endothelium can scavenge nitric oxide (NO),
avoiding NO-dependent vasodilation and stimulating the production of pro-inflammatory
agents and endothelium-derived vasoconstrictor factors [56].
The RAAS is another key factor in the maintenance of arterial BP. One of the main
components of this system is the ACE. In fact, the inhibition of this enzyme is usually used
to select antihypertensive compounds. ACE inhibitors such as Enalapril or Captopril are
usually used as treatment against HTN [57]. ACE catalyzes the conversion of angiotensin
I into the potent vasoconstrictor angiotensin II [58]. The ACEi properties of the soluble
fraction of the WL have been previously reported [19]. Since the ACEi activity of phenolic
compounds has also been reported [17], the hydrolysate PWL, as expected, exerted a more
potent ACEi activity than its control counterpart 0 WL.
Subsequently, the antihypertensive effect of the hydrolysate was evaluated in vivo,
using SHR as a hypertensive animal model. This is the one well-established of the
most used experimental models of HTN, very similar to the HTN found in humans [59].
The administration of 5 mL/kg bw of the hydrolysate produced a potent antihyperten-
sive effect, reaching the maximum SBP decrease between 4 and 8 h post-administration
(−32.29 ± 1.46 mmHg). In addition, this effect was long lasting, remaining until 48 h post
administration. A similar time response of the SBP-lowering effect has been shown by
hydrolysates obtained from other food by-products such as garlic protein hydrolysates,
which exhibited the maximum effect between 4–6 h post-administration [60]. It is notewor-
thy that, since it lasted longer, the antihypertensive effect of the PWL was more potent than
the one shown by the commercially available drug Captopril or the 0 WL. Considering
that HTN is a chronic pathology that needs lifetime treatment, the use of strategies with
long lasting antihypertensive effects is always desired. Therefore, the antihypertensive
properties of PWL seem more favorable.
It is known that phenolic compounds have numerous effects on health, including
antihypertensive effects [61]. The improvement of the antihypertensive effect of the WL
using enzymatic hydrolysis is linked to the release of phenolic compounds. In this sense,
intake of compounds rich in anthocyanins has shown to be associated with a lower arterial
stiffness and with a reduction in BP [62–64]. More specifically, malvidin-3-glucoside,
present in high amounts in the PWL, has shown to be a potent vasodilator [65]. Furthermore,
compounds rich in flavanols such as catechin, epicatechin or procyanidins, have been
shown to have antihypertensive effect in rats and humans [9,66,67]. In our previous study,
we also related the WL bioactivity to the content of flavanols and anthocyanins [19], which
is in line with the present results. Moreover, PWL showed an increment in flavonols,
especially in quercetin. It is known that flavonols, such as quercetin, improve vascular
endothelial function and reduce BP [68,69]. In this regard, several studies have reported
BP- lowering effects of quercetin in several animal models of HTN (10 mg/kg/day for 4 or
5 weeks) and in hypertensive patients (730 mg/day for 28 days) [70,71]. In addition, PWL
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also presented high levels of gallic acid. Kang et al. showed that the administration of
40 mg/kg bw of this phenolic acid to SHR produced an antihypertensive effect similar to
the observed by Captopril [72].
Taken together, the data obtained in this study show that the hydrolysis of WL is a
good strategy to release phenolic compounds, specifically anthocyanins and flavonols, and
the results strongly suggest that these phenolic compounds enhance the antihypertensive
effect of WL. Moreover, taking into account that WL also contain ethanol, which can reach
values similar to wine of at least 8.5% [73], an improvement of WL antihypertensive activity
using dealcoholized WL might be attained.
5. Conclusions
The phenolic extraction from the solid fraction of WL via enzymatic hydrolysis is
a useful method to obtain phenolic-enriched WL with enhanced antioxidant, ACEi and
antihypertensive properties. As a result, a WL fraction rich in flavanols, anthocyanins,
phenolic acids, and flavonols was obtained. The phenolic composition is considered of spe-
cial relevance since multiple beneficial effects have been linked to these phenolic families,
including antihypertensive properties. Therefore, this study opens the door to the wine
industry for the commercial use of PWL due to its high content of phenolic compounds.
Moreover, the enzyme-assisted extraction of phenolic compounds also modified the amino
acid content of WL, indicating that protein hydrolysis was taking place. Therefore, the
release of other molecules with antihypertensive properties, different to phenolic com-
pounds, such as bioactive peptides should not be ruled out. Moreover, as in addition to
phenolic compounds, WL contains ethanol, it would be of interest to investigate the BP-
lowering effect of the dealcoholized WL samples. Finally, further studies would be needed
to confirm the long-term effect of PWL in hypertensive and normotensive rats.
6. Patents
Patent application “Wine lees, derivatives thereof and their uses”: application number
EP20382358.8 and and PCT/EP2021/053051.
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